A federal court in Delaware denied Baxalta’s request for a new trial in a suit brought by Bayer over patent infringement by Baxalta’s hemophilia A drug Adynovate.  

The Takeda subsidiary sought a new trial on the grounds that its clotting factor VIII drug could not infringe on Bayer’s patent for factor VIII because the patent was invalid. 

Bayer sued Baxalta and Nektar Pharmaceuticals in 2016 alleging that they infringed on its patent by making, selling and importing Adynovate. Nektar had worked with Bayer on its version of the drug, but also helped Baxalta develop Adynovate, according to Bayer’s complaint.